SCHEMBL19970852

SCHEMBL19970852

COC(=O)c1ccc(COc2ccccc2CN2CCN(Cc3ccc4[nH]c(-c5ccccn5)nc4c3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.42
GCK P35557 5/20 0.42
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41
CBFB Q13951 3/20 0.40
MAPT P10636 1/20 0.40
FAAH O00519 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
PKM P14618 2/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
NFKB1 P19838 1/20 0.39
RAB9A P51151 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ACACB O00763 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970855 0.94 CBFB (0.47) LMNAGCKKMT2AMEN1CBFB
SCHEMBL19970731 0.93 ACACB (0.45) LMNAGCKKMT2AMEN1FAAH
SCHEMBL23828686 0.90 LMNA (0.48) LMNAKMT2AMEN1FAAHKDM4E
SCHEMBL19970732 0.88 ACACB (0.52) LMNAGCKCBFBKDM4EALDH1A1
SCHEMBL19970886 0.87 KIT (0.44) LMNAKMT2AMEN1FAAHKDM4E
SCHEMBL19970822 0.85 LMNA (0.45) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL19970765 0.84 SLC2A1 (0.41) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL19982681 0.83 HDAC6 (0.50) LMNAKMT2AMEN1KDM4EALDH1A1
SCHEMBL19970802 0.83 MEN1 (0.43) LMNAKMT2AMEN1MAPTFAAH
SCHEMBL19970844 0.82 LMNA (0.46) LMNAKMT2AMEN1FAAHKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS LMNA 614/4885GCK 2074/4885KMT2A 3401/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS LMNA 614/4885GCK 2074/4885KMT2A 3401/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.